UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals
In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $22.00 to $24.00.
Jefferies noted, “At its investor event in New York on 10/23/12, AEGR focused on clinical aspects of lomitapide in HoFH, hosting a panel of 2 lipidologists. There was no commercial agenda. AEGR expects to provide its commercial strategy in early-January 2013 as it is confident of FDA approval of lomitapide by PDUFA date 12/29/12 and EU approval in 1H13. Lomitapide received positive FDA panel votes (13-2 in favor) on 10/17/12.”
Aegerion Pharmaceuticals closed on Tuesday at $20.45.
Latest Ratings for AEGR
|Feb 2016||Bank of America||Downgrades||Neutral||Underperform|
|Nov 2015||Bank of America||Upgrades||Underperform||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.